This article highlights the clinical benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors and explores the underlying mechanisms responsible for their cardiovascular effects. The findings underscore the significant cardiovascular benefits of SGLT2 inhibitors, emphasizing their potential as an effective therapeutic option and contributing to improved patient outcomes in cardiovascular disease management. This evidence concerns the gene SLC5A2 and cardiovascular disorder.